Clinical Trial Update: CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating CART19, autologous CD19-directed CAR T cells, for systemic lupus erythematosus and lupus nephritis. The study is sponso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• CART19 (CD19-directed chimeric antigen receptor T cells)

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: SLE, Systemic Lupus Erythematosus (SLE) | Phase 1, Phase 2 | Status: RECRUITING